해부 병리학 시장 예측(-2031년) : 유형별, 프로세스별, 질환별, 최종사용자별, 지역별

The anatomic pathology market is projected to grow from USD 8.9 billion in 2026 to USD 14.5 billion by 2031, at a CAGR of 10.2%. The increasing global prevalence of cancer and other chronic diseases is driving demand for histopathology, cytopathology, and biomarker-based diagnostic testing. As healthcare systems increasingly adopt personalized medicine approaches, the need for accurate tissue characterization and biomarker assessment is expanding across a wide range of cancer types.

Furthermore, advancements in digital pathology, artificial intelligence, laboratory automation, and multiplex tissue analysis technologies are improving diagnostic efficiency, workflow standardization, and clinical decision-making. These innovations are enabling healthcare providers to deliver more accurate and timely diagnoses, thereby supporting the growth of the anatomic pathology market.

"The breast cancer segment is expected to account for the largest share of the anatomic pathology market, by disease type."

Based on disease type, the anatomic pathology market is segmented into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer (NSCLC), and other diseases. The breast cancer segment accounts for the largest market share due to the high global incidence of the disease and the extensive use of anatomic pathology techniques for disease diagnosis, classification, grading, and treatment planning. Pathology laboratories routinely utilize histopathology, immunohistochemistry (IHC), in situ hybridization (ISH), and biomarker assessment to support comprehensive evaluation of breast tissue specimens. Additionally, the increasing emphasis on early cancer detection, growing breast cancer screening initiatives, and rising demand for accurate pathological characterization continue to drive the adoption of anatomic pathology solutions, making breast cancer the largest disease segment within the market.

"The hospitals segment is expected to account for the largest share of the anatomic pathology market."

The global anatomic pathology market can be segmented by end user into hospitals, research laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users. Among these, the hospitals segment accounted for the largest market share. Hospitals remain the primary setting for anatomic pathology testing due to the high volume of cancer diagnoses, surgical procedures, and tissue-based examinations performed within integrated healthcare systems. Furthermore, the increasing availability of advanced pathology infrastructure, growing adoption of laboratory automation and digital pathology technologies, and rising demand for timely and accurate diagnostic services are expected to support the continued utilization of anatomic pathology solutions across hospital-based laboratories worldwide.

"The Asia Pacific is the fastest-growing market for anatomic pathology from 2026 to 2031."

The global anatomic pathology market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. The region is witnessing a rapid increase in cancer incidence, creating significant demand for histopathology, cytopathology, and biomarker-based diagnostic services. China is expanding pathology laboratory capacity through healthcare infrastructure modernization initiatives and increasing investments in cancer diagnostics. India's growing network of tertiary-care hospitals, cancer centers, and private diagnostic laboratories is accelerating the adoption of advanced pathology technologies and laboratory automation. Meanwhile, Japan's aging population, high cancer screening rates, and increasing adoption of digital pathology solutions continue to support the expansion of the anatomic pathology market across the region.

The break-up of the profiles of primary participants in the anatomic pathology market:

• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level Executives (27%), Directors (18%), and Others (55%)
• By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Hologic, Inc. (US), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (US), Koninklijke Philips N.V. (Netherlands), Merck KGaA (Germany), Bio SB (US), and Sakura Finetek Japan Co., Ltd. (Japan) are some of the key players in the anatomic pathology market.

Research Coverage:

This research report categorizes the anatomic pathology market into the product market by type (consumables, instruments, software, and storage systems), product market by process (preanalytics/sample preparation, advanced staining/IHC, primary & special staining, and digital pathology), product market by disease (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer, and other diseases), product market by end user (hospitals, research laboratories, pharmaceutical companies, contract research organizations, and other end users), service market by type (histopathology services and cytopathology services), service market by model (in-house and outsourced), service market by disease (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer, and other diseases), and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the anatomic pathology market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions; key strategies such as acquisitions, agreements, and product & service launches; and recent developments associated with the anatomic pathology market. Competitive analysis of upcoming startups in the anatomic pathology market ecosystem is covered in this report.

Reasons to buy this report:

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall anatomic pathology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (high incidence of cancer and other target diseases, growing demand for digital pathology, availability of reimbursement, and growing focus on personalized medicine), restraints (high cost of instruments and consumables), opportunities (expansion potential across emerging economies and increasing number of clinical trials for cancer therapeutics), and challenges (availability of refurbished products, stringent regulatory requirements, and shortage of skilled professionals) influencing the growth of the anatomic pathology market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the anatomic pathology market.
• Market Development: Comprehensive information about lucrative markets-the report analyzes the anatomic pathology market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the anatomic pathology market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Hologic, Inc. (US), Agilent Technologies, Inc. (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 ANATOMIC PATHOLOGY PRODUCT MARKET OVERVIEW
• 3.2 ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE, 2026 VS. 2031
• 3.3 ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS, 2026 VS. 2031
• 3.4 ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE, 2026 VS. 2031
• 3.5 ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER, 2026 VS. 2031
• 3.6 ANATOMIC PATHOLOGY PRODUCT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 High incidence of cancer and other target diseases
    • 4.2.1.2 Growing demand for digital pathology
    • 4.2.1.3 Availability of reimbursement
    • 4.2.1.4 Growing focus on personalized medicine
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High cost of instruments and consumables
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Expansion potential across emerging economies
    • 4.2.3.2 Increasing number of clinical trials for cancer therapeutics
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Availability of refurbished products
    • 4.2.4.2 Stringent regulatory requirements
    • 4.2.4.3 Shortage of skilled professionals
• 4.3 UNMET NEEDS & WHITE SPACES
  • 4.3.1 UNMET NEEDS IN ANATOMIC PATHOLOGY MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
  • 4.5.1 KEY MOVES & STRATEGIC FOCUS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF NEW ENTRANTS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 ANATOMIC PATHOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE OF ANATOMIC PATHOLOGY PRODUCTS, BY KEY PLAYER, 2024-2026
  • 5.6.2 AVERAGE SELLING PRICE OF ANATOMIC PATHOLOGY PRODUCTS, BY REGION, 2024-2026
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
  • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
• 5.8 KEY CONFERENCES & EVENTS, 2026-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.10 INVESTMENT & FUNDING SCENARIO
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 CASE STUDY 1: OPTIMIZING AUTOMATED TISSUE PROCESSING EFFICIENCY TO REDUCE COST
  • 5.11.2 CASE STUDY 2: OPERATIONAL EFFICIENCY IMPROVEMENTS THROUGH MILESTONE MEDICAL TISSUE PROCESSOR IMPLEMENTATION
  • 5.11.3 CASE STUDY 3: WORKFLOW OPTIMIZATION THROUGH EXCELSIOR AS TISSUE PROCESSOR
• 5.12 IMPACT OF 2025 US TARIFFS ON ANATOMIC PATHOLOGY MARKET
  • 5.12.1 INTRODUCTION
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 IMPACT ON REGION
    • 5.12.4.1 North America
    • 5.12.4.2 Europe
    • 5.12.4.3 Asia Pacific
  • 5.12.5 IMPACT ON END-USE INDUSTRIES
    • 5.12.5.1 Hospitals
    • 5.12.5.2 Research laboratories
    • 5.12.5.3 Pharmaceutical companies
    • 5.12.5.4 Contract research organizations (CROs)

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 HISTOPATHOLOGY
  • 6.1.2 CYTOPATHOLOGY
  • 6.1.3 DIGITAL PATHOLOGY
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 SPECIAL STAINING
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 MASS SPECTROMETRY IMAGING (MSI)
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.4.1 SHORT-TERM (2025-2027) | OPTIMIZATION & STANDARDIZATION OF CORE REAGENTS
    • 6.4.1.1 Core technology development
    • 6.4.1.2 Product innovations
    • 6.4.1.3 Market adoption
  • 6.4.2 MID-TERM (2027-2030) | EXPANDED CAPABILITIES & SUSTAINABILITY
    • 6.4.2.1 Advanced technology development
    • 6.4.2.2 Product innovations
    • 6.4.2.3 Market adoption
  • 6.4.3 LONG-TERM (2030-2035+) | HIGH-PERFORMANCE & ECO-EFFICIENT PRODUCTS
    • 6.4.3.1 High-performance & integrated workflows
    • 6.4.3.2 Product innovations
    • 6.4.3.3 Market adoption
• 6.5 PATENT ANALYSIS
  • 6.5.1 LIST OF MAJOR PATENTS
    • 6.5.1.1 List of key patents
• 6.6 FUTURE APPLICATIONS
• 6.7 IMPACT OF AI/GENERATIVE AI ON ANATOMIC PATHOLOGY MARKET
  • 6.7.1 INTRODUCTION
  • 6.7.2 TOP USE CASES & MARKET POTENTIAL
  • 6.7.3 KEY COMPANIES IMPLEMENTING AI
  • 6.7.4 FUTURE OF AI

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY ANALYSIS
    • 7.1.1.1 North America
      • 7.1.1.1.1 US
      • 7.1.1.1.2 Canada
    • 7.1.1.2 Europe
      • 7.1.1.2.1 Germany
      • 7.1.1.2.2 UK
      • 7.1.1.2.3 France
    • 7.1.1.3 Asia Pacific
      • 7.1.1.3.1 China
      • 7.1.1.3.2 Japan
      • 7.1.1.3.3 India
    • 7.1.1.4 Latin America
    • 7.1.1.5 Middle East
      • 7.1.1.5.1 Africa
  • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN ANATOMIC PATHOLOGY MARKET
    • 7.2.1.1 Eco-friendly initiatives
• 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY
  • 8.5.1 REVENUE POTENTIAL
  • 8.5.2 COST DYNAMICS
  • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE

• 9.1 INTRODUCTION
• 9.2 CONSUMABLES
  • 9.2.1 HISTOPATHOLOGY CONSUMABLES
    • 9.2.1.1 Histopathology antibodies
      • 9.2.1.1.1 Primary histopathology antibodies
        • 9.2.1.1.1.1 Increasing adoption of precision medicine to drive market growth
      • 9.2.1.1.2 Secondary histopathology antibodies
        • 9.2.1.1.2.1 Growing focus on highly specific polymers to drive demand for histopathology secondary antibodies
    • 9.2.1.2 Histopathology kits & reagents
      • 9.2.1.2.1 Histopathology stains & solvents
        • 9.2.1.2.1.1 Increasing adoption of advanced tissue staining techniques to drive growth of histopathology stains & solvents
      • 9.2.1.2.2 Histopathology fixatives
        • 9.2.1.2.2.1 Growing emphasis on tissue preservation and biomarker integrity to drive demand for histopathology fixation reagents
      • 9.2.1.2.3 Other histopathology kits & reagents
    • 9.2.1.3 Histopathology probes
      • 9.2.1.3.1 Growing adoption of tissue-based pathology and precision diagnostics to drive demand for histopathology probes
    • 9.2.1.4 Other histopathology consumables
  • 9.2.2 CYTOPATHOLOGY CONSUMABLES
    • 9.2.2.1 Cytopathology antibodies
      • 9.2.2.1.1 Primary cytopathology antibodies
        • 9.2.2.1.1.1 Advancements in biomarker research using cell analysis to support market growth
      • 9.2.2.1.2 Secondary cytopathology antibodies
        • 9.2.2.1.2.1 Expanding use of cytopathology for cancer screening to accelerate demand
    • 9.2.2.2 Cytopathology kits & reagents
      • 9.2.2.2.1 Cytopathology stains & solvents
        • 9.2.2.2.1.1 Growing demand for cytology-based screening and cellular diagnostics to fuel cytopathology stains & solvents market
      • 9.2.2.2.2 Cytopathology fixatives
        • 9.2.2.2.2.1 Rising adoption of cytology-based screening and liquid-based cytology to support growth of cytopathology fixation reagents
      • 9.2.2.2.3 Other cytopathology kits & reagents
    • 9.2.2.3 Cytopathology probes
      • 9.2.2.3.1 Increasing research to aid market growth
    • 9.2.2.4 Other cytopathology consumables
• 9.3 INSTRUMENTS
  • 9.3.1 SLIDE STAINING SYSTEMS
    • 9.3.1.1 Availability of automated systems to drive market growth
  • 9.3.2 TISSUE PROCESSING SYSTEMS
    • 9.3.2.1 Rising adoption of automation to drive market growth
  • 9.3.3 CELL PROCESSORS
    • 9.3.3.1 Technological advancements in cytopathology testing to support growth of this market
  • 9.3.4 MICROTOMES
    • 9.3.4.1 Increasing demand for accurate tissue sectioning to support growth
  • 9.3.5 EMBEDDING SYSTEMS
    • 9.3.5.1 Advancements in tissue preparation technologies to support expansion of embedding systems market
  • 9.3.6 COVERSLIPPERS
    • 9.3.6.1 Increasing focus on laboratory automation and workflow efficiency to drive growth of coverslippers market
  • 9.3.7 DIGITAL PATHOLOGY SCANNERS
    • 9.3.7.1 Growing adoption of digital imaging to propel market
  • 9.3.8 OTHER INSTRUMENTS
• 9.4 SOFTWARE
  • 9.4.1 AI-INTEGRATED SOFTWARE
    • 9.4.1.1 Growing adoption of artificial intelligence in pathology workflows to accelerate demand for AI-integrated software
  • 9.4.2 NON-AI-INTEGRATED SOFTWARE
    • 9.4.2.1 Increasing digitalization of pathology laboratories to drive demand for non-AI pathology software
• 9.5 STORAGE SYSTEMS
  • 9.5.1 GROWING ADOPTION OF DIGITAL PATHOLOGY AND INCREASING DATA VOLUMES TO DRIVE DEMAND FOR PATHOLOGY STORAGE SYSTEMS

10 ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS

• 10.1 INTRODUCTION
• 10.2 PREANALYTICS/SAMPLE PREPARATION
  • 10.2.1 GROWING DEMAND FOR EFFICIENT SPECIMEN HANDLING AND LABORATORY AUTOMATION TO DRIVE GROWTH
• 10.3 ADVANCED STAINING/IHC
  • 10.3.1 GROWING ADOPTION OF MULTIPLEX BIOMARKER ANALYSIS AND AUTOMATED STAINING WORKFLOWS TO SUPPORT MARKET GROWTH
• 10.4 PRIMARY & SPECIAL STAINING
  • 10.4.1 GROWING DEMAND FOR SPECIALIZED TISSUE & CELLULAR CHARACTERIZATION TO DRIVE GROWTH
• 10.5 DIGITAL PATHOLOGY
  • 10.5.1 GROWING ADOPTION OF WHOLE-SLIDE IMAGING AND AI-ENABLED WORKFLOWS TO DRIVE GROWTH OF DIGITAL PATHOLOGY

11 ANATOMIC PATHOLOGY MARKET, BY DISEASE

• 11.1 INTRODUCTION
• 11.2 BREAST CANCER
  • 11.2.1 RISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO FUEL MARKET
• 11.3 NON-SMALL-CELL LUNG CANCER
  • 11.3.1 RISING CASES OF LUNG CANCER TO DRIVE ADOPTION
• 11.4 PROSTATE CANCER
  • 11.4.1 GROWING RATE OF PROSTATE CANCER TO PROPEL MARKET
• 11.5 GASTRIC CANCER
  • 11.5.1 RISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST MARKET
• 11.6 LYMPHOMA
  • 11.6.1 RISING INCIDENCE OF NON-HODGKIN'S LYMPHOMA IN ADULTS TO SUPPORT GROWTH
• 11.7 OTHER DISEASES

12 ANATOMIC PATHOLOGY MARKET VOLUME ANALYSIS, BY DISEASE (NUMBER OF TESTS)

13 ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 HOSPITALS
  • 13.2.1 RISING HEALTHCARE INVESTMENT TO CONTRIBUTE TO GROWTH
• 13.3 RESEARCH LABORATORIES
  • 13.3.1 RISING DEMAND FOR SPECIALTY TESTS TO DRIVE MARKET
• 13.4 PHARMACEUTICAL COMPANIES
  • 13.4.1 INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET
• 13.5 CONTRACT RESEARCH ORGANIZATIONS
  • 13.5.1 GROWING DEMAND FOR OUTSOURCING ANALYTICAL TESTING & CLINICAL TRIAL SERVICES TO BOOST MARKET
• 13.6 OTHER END USERS

14 ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE

• 14.1 INTRODUCTION
• 14.2 HISTOPATHOLOGY SERVICES
• 14.3 CYTOPATHOLOGY SERVICES

15 ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE

• 15.1 INTRODUCTION
• 15.2 IN-HOUSE
• 15.3 OUTSOURCED

16 ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE

• 16.1 INTRODUCTION
• 16.2 BREAST CANCER
  • 16.2.1 NON-SMALL CELL LUNG CANCER
  • 16.2.2 PROSTATE CANCER
  • 16.2.3 GASTRIC CANCER
  • 16.2.4 LYMPOMA
  • 16.2.5 OTHER DISEASE TYPE

17 ANATOMIC PATHOLOGY MARKET, BY REGION

• 17.1 INTRODUCTION
• 17.2 NORTH AMERICA
  • 17.2.1 US
    • 17.2.1.1 High healthcare expenditure to drive market
  • 17.2.2 CANADA
    • 17.2.2.1 Rising prevalence of cancer to fuel market
• 17.3 EUROPE
  • 17.3.1 GERMANY
    • 17.3.1.1 Favorable government initiatives to boost market
  • 17.3.2 UK
    • 17.3.2.1 Rising investments in cancer research to drive market
  • 17.3.3 FRANCE
    • 17.3.3.1 Increasing demand for cancer diagnostics to propel market
  • 17.3.4 ITALY
    • 17.3.4.1 High incidence of cancer and geriatric population to support growth
  • 17.3.5 SPAIN
    • 17.3.5.1 Increased cancer cases to boost market
  • 17.3.6 REST OF EUROPE
• 17.4 ASIA PACIFIC
  • 17.4.1 CHINA
    • 17.4.1.1 Increasing focus on healthcare infrastructure to boost market
  • 17.4.2 JAPAN
    • 17.4.2.1 Established healthcare system to fuel market
  • 17.4.3 INDIA
    • 17.4.3.1 Presence of large patient pool and rapidly growing healthcare sector to drive market
  • 17.4.4 REST OF ASIA PACIFIC
• 17.5 LATIN AMERICA
  • 17.5.1 GROWING ONCOLOGY PATIENT POOL, COMBINED WITH EXPANDING PUBLIC AND PRIVATE INVESTMENTS IN CANCER CARE, TO BOOST GROWTH
• 17.6 MIDDLE EAST & AFRICA
  • 17.6.1 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO AID ANATOMIC PATHOLOGY MARKET

18 COMPETITIVE LANDSCAPE

• 18.1 INTRODUCTION
• 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 18.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN ANATOMIC PATHOLOGY MARKET
• 18.3 REVENUE ANALYSIS, 2023-2025
• 18.4 MARKET SHARE ANALYSIS, 2025
  • 18.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
  • 18.4.2 US MARKET SHARE ANALYSIS, 2025
• 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 18.5.1 STARS
  • 18.5.2 EMERGING LEADERS
  • 18.5.3 PERVASIVE PLAYERS
  • 18.5.4 PARTICIPANTS
  • 18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 18.5.5.1 Company footprint
    • 18.5.5.2 Region footprint
    • 18.5.5.3 Type footprint
    • 18.5.5.4 Process footprint
    • 18.5.5.5 End-user footprint
• 18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 18.6.1 PROGRESSIVE COMPANIES
  • 18.6.2 RESPONSIVE COMPANIES
  • 18.6.3 DYNAMIC COMPANIES
  • 18.6.4 STARTING BLOCKS
  • 18.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 18.6.5.1 Detailed list of key startups/SMEs
    • 18.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
    • 18.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
• 18.7 COMPANY VALUATION & FINANCIAL METRICS
  • 18.7.1 FINANCIAL METRICS
  • 18.7.2 COMPANY VALUATION
• 18.8 BRAND/PRODUCT COMPARISON
• 18.9 COMPETITIVE SCENARIO
  • 18.9.1 PRODUCT LAUNCHES & APPROVALS
  • 18.9.2 DEALS
  • 18.9.3 EXPANSIONS

19 COMPANY PROFILES

• 19.1 KEY PLAYERS
  • 19.1.1 F. HOFFMANN-LA ROCHE LTD.
    • 19.1.1.1 Business overview
    • 19.1.1.2 Products offered
    • 19.1.1.3 Recent developments
      • 19.1.1.3.1 Product launches & approvals
      • 19.1.1.3.2 Deals
    • 19.1.1.4 MnM view
      • 19.1.1.4.1 Key strengths
      • 19.1.1.4.2 Strategic choices
      • 19.1.1.4.3 Weaknesses & competitive threats
  • 19.1.2 DANAHER CORPORATION
    • 19.1.2.1 Business overview
    • 19.1.2.2 Products offered
    • 19.1.2.3 Recent developments
      • 19.1.2.3.1 Product launches & approvals
      • 19.1.2.3.2 Deals
    • 19.1.2.4 MnM view
      • 19.1.2.4.1 Key strengths
      • 19.1.2.4.2 Strategic choices
      • 19.1.2.4.3 Weaknesses & competitive threats
  • 19.1.3 PHC HOLDINGS CORPORATION (EPREDIA)
    • 19.1.3.1 Business overview
    • 19.1.3.2 Products offered
    • 19.1.3.3 Recent developments
      • 19.1.3.3.1 Product launches & approvals
      • 19.1.3.3.2 Deals
    • 19.1.3.4 MnM view
      • 19.1.3.4.1 Key strengths
      • 19.1.3.4.2 Strategic choices
      • 19.1.3.4.3 Weaknesses & competitive threats
  • 19.1.4 AGILENT TECHNOLOGIES, INC.
    • 19.1.4.1 Business overview
    • 19.1.4.2 Products offered
    • 19.1.4.3 Recent developments
      • 19.1.4.3.1 Product launches
      • 19.1.4.3.2 Deals
    • 19.1.4.4 MnM view
      • 19.1.4.4.1 Key strengths
      • 19.1.4.4.2 Strategic choices
      • 19.1.4.4.3 Weaknesses & competitive threats
  • 19.1.5 HOLOGIC INC.
    • 19.1.5.1 Business overview
    • 19.1.5.2 Products offered
    • 19.1.5.3 Recent developments
      • 19.1.5.3.1 Product approvals
    • 19.1.5.4 MnM view
      • 19.1.5.4.1 Key strengths
      • 19.1.5.4.2 Strategic choices
      • 19.1.5.4.3 Weaknesses & competitive threats
  • 19.1.6 BECTON, DICKINSON AND COMPANY (BD)
    • 19.1.6.1 Business overview
    • 19.1.6.2 Products offered
    • 19.1.6.3 Recent developments
      • 19.1.6.3.1 Deals
      • 19.1.6.3.2 Expansions
  • 19.1.7 KONINKLIJKE PHILIPS N.V.
    • 19.1.7.1 Business overview
    • 19.1.7.2 Products offered
    • 19.1.7.3 Recent developments
      • 19.1.7.3.1 Deals
      • 19.1.7.3.2 Expansions
  • 19.1.8 MERCK KGAA
    • 19.1.8.1 Business overview
    • 19.1.8.2 Products offered
    • 19.1.8.3 Recent developments
      • 19.1.8.3.1 Expansions
  • 19.1.9 SECTRA AB
    • 19.1.9.1 Business overview
    • 19.1.9.2 Products offered
    • 19.1.9.3 Recent developments
      • 19.1.9.3.1 Product approvals
      • 19.1.9.3.2 Deals
      • 19.1.9.3.3 Expansions
  • 19.1.10 SAKURA FINETEK JAPAN CO., LTD.
    • 19.1.10.1 Business overview
    • 19.1.10.2 Products offered
    • 19.1.10.3 Recent developments
      • 19.1.10.3.1 Product launches
      • 19.1.10.3.2 Deals
      • 19.1.10.3.3 Expansions
• 19.2 OTHER PLAYERS
  • 19.2.1 BIO SB
  • 19.2.2 BIOGENEX
  • 19.2.3 MILESTONE MEDICAL
  • 19.2.4 HISTO-LINE LABORATORIES
  • 19.2.5 DIAPATH S.P.A.
  • 19.2.6 SLEE MEDICAL GMBH
  • 19.2.7 AMOS SCIENTIFIC PTY LTD.
  • 19.2.8 MEDITE MEDICAL GMBH
  • 19.2.9 CELL SIGNALING TECHNOLOGY, INC.
  • 19.2.10 CELLPATH LTD.
  • 19.2.11 MICROS AUSTRIA
  • 19.2.12 R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED
  • 19.2.13 RWD LIFE SCIENCE CO., LTD.
  • 19.2.14 MEDIMEAS
  • 19.2.15 BRIGHT INSTRUMENTS
  • 19.2.16 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.
  • 19.2.17 HAMAMATSU PHOTONICS K.K.
  • 19.2.18 3DHISTECH LTD.
  • 19.2.19 OPTRASCAN
  • 19.2.20 DAKEWE

20 RESEARCH METHODOLOGY

• 20.1 RESEARCH DATA
  • 20.1.1 SECONDARY DATA
    • 20.1.1.1 List of secondary sources
    • 20.1.1.2 Key data from secondary sources
  • 20.1.2 PRIMARY DATA
    • 20.1.2.1 Breakdown of primary interviews
• 20.2 MARKET SIZE ESTIMATION
  • 20.2.1 TOTAL MARKET SIZE: ANATOMIC PATHOLOGY MARKET
  • 20.2.2 BOTTOM-UP APPROACH
    • 20.2.2.1 Approach 2: Study of annual reports and investor presentations
    • 20.2.2.2 Approach 3: Primary interviews
    • 20.2.2.3 Growth forecast
  • 20.2.3 TOP-DOWN APPROACH
• 20.3 DATA TRIANGULATION
• 20.4 RESEARCH ASSUMPTIONS
  • 20.4.1 STUDY-RELATED ASSUMPTIONS
• 20.5 STUDY ASSUMPTIONS
  • 20.5.1 PARAMETRIC ASSUMPTIONS
  • 20.5.2 GROWTH RATE ASSUMPTIONS
• 20.6 RESEARCH LIMITATIONS
• 20.7 RISK ASSESSMENT

21 APPENDIX

• 21.1 DISCUSSION GUIDE
• 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 21.3 CUSTOMIZATION OPTIONS
• 21.4 RELATED REPORTS
• 21.5 AUTHOR DETAILS